hit counter
AzurRx BioPharma, Inc. (AZRX) Stock News Sentiment & Price - Sentifly
AZRX - Sentifly


Profile

Watchlist

Your watchlist is empty. Go add some tickers to it!



AzurRx BioPharma, Inc. (AZRX)

USA
Biotechnology
NASDAQ
AZRX Price and Sentiment
1MO
1D
Positive, Negative
Loading chart...
AZRX Latest news
GlobeNewsWire
Neutral
AzurRx BioPharma to Change Corporate Name to First Wave BioPharma Today
2021-09-21 12:47

Company to begin trading on Nasdaq under new ticker symbol, “FBWI”, effective September 22 Company to begin trading on Nasdaq under new ticker symbol, “FBWI”, effective September 22

PennyStocks
Positive
3 Penny Stocks That Top Investors Buying Right Now
2021-09-15 09:20

Which penny stocks are you watching in September 2021? Here's three for some watchlist inspiration The post 3 Penny Stocks That Top Investors Buying Right Now appeared first on Penny Stocks to Buy, Picks, News and Information | PennyStocks.com.

Zacks Investment Research
Positive
AzurRx (AZRX) Announces First Wave Bio Acquisition for $229M
2021-09-14 12:59

AzurRx BioPharma (AZRX) acquires First Wave Bio for $229 million. Following the acquisition, the company is set to rename itself as First Wave BioPharma.

GlobeNewsWire
Neutral
AzurRx BioPharma CEO Issues Letter to Shareholders Regarding Recent Acquisition of First Wave Bio and Creation of First Wave BioPharma
2021-09-14 07:30

BOCA RATON, Fla., Sept. 14, 2021 (GLOBE NEWSWIRE) -- AzurRx BioPharma, Inc. (NASDAQ:AZRX), (“First Wave BioPharma” or the “Company”), a clinical-stage biopharmaceutical company specializing in the development of targeted, non-systemic therapies for gastrointestinal (GI) diseases, today issued a letter to its shareholders from James Sapirstein, President, Chief Executive Officer and Chairman, regarding its recently announced merger with First Wave Bio, Inc. and adoption of the First Wave BioPharma name. The full text of the letter, which has also been posted to the Company's website, is as follows:

Seeking Alpha
Neutral
AzurRx BioPharma, Inc. (AZRX) CEO James Sapirstein on First Wave Bio Acquisition - Conference Call Transcript
2021-09-13 16:40

AzurRx BioPharma, Inc. (AZRX) CEO James Sapirstein on First Wave Bio Acquisition - Conference Call Transcript

Benzinga
Positive
AzurRx BioPharma Announces Reverse Merger With First Wave Bio
2021-09-13 09:19

AzurRx BioPharma Inc (NASDAQ: AZRX) has agreed to acquire First Wave Bio Inc in a stock and cash transaction valued at $229 million, including milestone payments.  First Wave Bio is a clinical-stage biotechnology company specializing in developing gut-targeted, small molecule therapies for autoimmune inflammatory bowel diseases (IBD).

GlobeNewsWire
Neutral
AzurRx BioPharma Announces Acquisition of First Wave Bio and its Proprietary Niclosamide Formulations Targeting Multi-Billion Dollar Inflammatory Bowel Disease Indications
2021-09-13 06:00

AzurRx BioPharma to be renamed “First Wave BioPharma” and trade under new NASDAQ ticker symbol, “FWBI”

GlobeNewsWire
Neutral
AzurRx BioPharma Announces Reverse Stock Split
2021-09-10 12:45

Common Stock Will Begin Trading on Split-Adjusted Basis on September 13, 2021 Common Stock Will Begin Trading on Split-Adjusted Basis on September 13, 2021

GlobeNewsWire
Neutral
AzurRx BioPharma Activates New Clinical Trial Sites in India for Phase 2 RESERVOIR Trial Evaluating Niclosamide for the Treatment of COVID-19 Gastrointestinal Infections
2021-09-10 08:30

Phase 2 placebo-controlled clinical trial to confirm safety of FW-1022 and investigate its ability to remove SARS-CoV-2 virus from the GI tract Phase 2 placebo-controlled clinical trial to confirm safety of FW-1022 and investigate its ability to remove SARS-CoV-2 virus from the GI tract

Loading more news...